Utilization of a CMV T Cell Immunity Panel in Directing Duration of Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

被引：0
|
作者：
Ray, A. [1 ]
Garner, B. [1 ]
Klein, C. [1 ]
机构：
[1] Piedmont Transplant Inst, Atlanta, GA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B84
引用
收藏
页码：S793 / S793
页数：1
相关论文
共 50 条
  • [31] Real-World Experience With CMV inSIGHT T Cell Immunity Testing in High-Risk Kidney and Pancreas Transplant Recipients
    Descourouez, Jillian L.
    Smith, Jeannina A.
    Saddler, Christopher M.
    Mandelbrot, Didier A.
    Odorico, Jon S.
    Jorgenson, Margaret R.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 796 - 802
  • [32] Increased Incidence of Leucopenia With FDA Approved Valganciclovir Dosing for CMV Prophylaxis in Pediatric Kidney Transplant Recipients.
    Bhatnagar, S.
    Palma, K.
    Palmer, J.
    Baluarte, J.
    Amaral, S.
    TRANSPLANTATION, 2014, 98 : 501 - 501
  • [33] Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
    Johansson, Inger
    Martensson, Gunnar
    Nystrom, Ulla
    Nasic, Salmir
    Andersson, Rune
    BMC INFECTIOUS DISEASES, 2013, 13
  • [34] A prospective trial of valganciclovir prophylaxis for cytomegalovirus (CMV) prevention in lung transplant recipients.
    Humar, A
    Kumar, D
    Preiksaitis, J
    Fenton, J
    Nia, S
    Jackson, K
    Chernenko, S
    Lien, D
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 270 - 270
  • [35] Ganciclovir vs. valganciclovir for CMV prophylaxis in solitary pancreas transplant recipients.
    Rea, DJ
    Kudva, YC
    Larson, TS
    Stegall, MD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 380 - 380
  • [36] Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
    Inger Johansson
    Gunnar Mårtensson
    Ulla Nyström
    Salmir Nasic
    Rune Andersson
    BMC Infectious Diseases, 13
  • [37] Impact of Prolonging CMV Prophylaxis in High Risk (CMV D plus /R-) Lung Transplant Recipients
    Khan, B.
    Husain, S.
    Binnie, M.
    Chow, C.
    Martinu, T.
    Chaparro, C.
    Keshavjee, S.
    Singer, L. G.
    Tikkanen, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S319 - S319
  • [38] The problem of cytomegalovirus (CMV) prophylaxis in high-risk renal transplant recipients
    Maiwald, J
    Sperschneider, H
    Stein, G
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (09) : 1897 - 1897
  • [39] Efficacy of CMV Immunoglobulin as Cytomegalovirus Prophylaxis in High Risk Lung Transplant Recipients
    Donkin, J. D.
    Girgis, R.
    Lawson, C. K.
    Hassouna, H.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S457 - S458
  • [40] CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients
    Donadeu, Laura
    Revilla-Lopez, Eva
    Jarque, Marta
    Crespo, Elena
    Torija, Alba
    Bravo, Carles
    Los Arcos, Ibai
    Meneghini, Maria
    Fava, Alex
    Roman, Antonio
    Monforte, Victor
    Bestard, Oriol
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (03): : 526 - 531
12345